Ypsomed Holding AG
🇬🇧XLON.0QLQUnited KingdomNot reported
Price£358.80-5.80 (-1.59%)
Latest anomalies
Neutral 1 detected in the last 120 days
- High: 10
- Medium: 2
- Low: 0
12-1M momentum: flipped sign, from negative to positive
Cash conversion cycle: a sudden drop below its trailing quarter average
Days sales outstanding: a sudden drop below its trailing quarter average
Financial leverage: a sudden drop below its trailing quarter average
Fixed asset turnover: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- United Kingdom
Identity
- Exchange
- London Stock Exchange . XLON
- Type
- Stock
- ISIN
- Not reported
- CUSIP
- Not reported
Company
- Employees
- 2,000
- Headquarters
- Burgdorf, United Kingdom
- Website
- https://www.ypsomed.com
Market
- Shares outstanding
- 12.6M
- Market cap
- £4.5B
Highlights
- Market cap
- £4.5B
- EPS LTM
- CHF 6.41
- P/E LTM
- 52.89
- Div yield
- 0.59%
Fundamentals (LTM)
- Revenue
- CHF 748.87M-8.97%down year on year
- Net income
- CHF 87.5M-25.56%down year on year
- Gross margin
- 39%+7.37%up year on year
- Free cash flow
- -CHF 57.4M-288.59%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Ypsomed Holding AG is listed on London Stock Exchange (United Kingdom) under the ticker 0QLQ. Its market capitalisation is £4.5B, from 12.6M shares outstanding, as of . Across the 248 trading sessions to the shares traded between £263.50 and £417.00, and the last close of £358.80 sits 62% of the way up that range. The company is headquartered in Burgdorf, United Kingdom, and employs about 2,000 people. This is the London Stock Exchange listing of Ypsomed Holding AG; its primary listing is YPSN on SIX Swiss Exchange.
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.